Passa al contenuto
Merck
Tutte le immagini(3)

Documenti

SML0005

Sigma-Aldrich

Cerivastatin sodium salt hydrate

≥98% (HPLC)

Sinonimo/i:

(3R,5S,6E)-7-[4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoic acid sodium salt hydrate, Rivastatin hydrate

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C26H33FNNaO5 · xH2O
Numero CAS:
Peso molecolare:
481.53 (anhydrous basis)
Numero MDL:
Codice UNSPSC:
12352200
ID PubChem:
NACRES:
NA.77

Saggio

≥98% (HPLC)

Forma fisica

powder

Attività ottica

[α]/D +18 to +26° in ethanol

Condizioni di stoccaggio

desiccated

Colore

white to tan

Solubilità

H2O: ≥5 mg/mL

Ideatore

Bayer

Temperatura di conservazione

2-8°C

Stringa SMILE

O.[Na+].COCc1c(nc(C(C)C)c(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)c1-c2ccc(F)cc2)C(C)C

InChI

1S/C26H34FNO5.Na.H2O/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4;;/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32);;1H2/q;+1;/p-1/b11-10+;;/t19-,20-;;/m1../s1
NJHMEKXCHXHQPP-PZLZTSNUSA-M

Descrizione generale

Cerivastatin sodium salt hydrate belongs to the statin class of lipid lowering agents. It helps in decreasing MAP kinase activation, blocking AP-1 (activator protein-1) and NF-kB (nuclear factor-kB ) binding activity, inhibiting inflammatory responses and ameliorated renal damage. It also lowers cholesterol. It is metabolized by cytochrome P450 (CYP)3A4 and (CYP)2C8. Cerivastatin sodium salt hydrate is linked to rhabdomyolysis.

Applicazioni

Cerivastatin sodium salt hydrate has been used as a supplement in cell culture.
Cerivastatin sodium salt hydrate may be used in cell signaling studies.

Azioni biochim/fisiol

Accumulated macrophages in atherosclerotic plaques result in plaque rupture and thrombus formation. Cerivastatin suppresses the growth of macrophages and decreases the expression of matrix metalloproteinases and tissue factor molecules, thus reduces acute coronary events.
Cerivastatin sodium is an HMG-CoA reductase inhibitor. HMG-CoA is a key enzyme in the production of cholesterol.

Caratteristiche e vantaggi

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 4

1 of 4

Lovastatin Lovastatin, CAS 75330-75-5, is an anti-hypercholesterolemic agent that inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.

Sigma-Aldrich

438185

Lovastatin

Mevinolina ≥98% (HPLC)

Sigma-Aldrich

M2147

Mevinolina

Telmisartan ≥98% (HPLC), solid

Sigma-Aldrich

T8949

Telmisartan

Simvastatin analytical standard

Supelco

38956

Simvastatin

Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin
Mazzu AL, et al.
Clinical Pharmacology and Therapeutics, 68(4), 391-400 (2000)
Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure-and cholesterol-lowering effects
Park JK, et al.
Kidney International, 58(4), 1420-1430 (2000)
GTSE1: a novel TEAD4-E2F1 target gene involved in cell protrusions formation in triple-negative breast cancer cell models
Stelitano D, etal.
Oncotarget, 8(40), 67422-67422 (2017)
A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin
Ishikawa C, et al.
Journal of Human Genetics, 49(10), 582-585 (2004)
M Aikawa et al.
Circulation, 103(2), 276-283 (2001-02-24)
Unstable atherosclerotic plaques that cause acute coronary events usually contain abundant macrophages expressing matrix metalloproteinases (MMPs) and tissue factor (TF), molecules that probably contribute to plaque rupture and subsequent thrombus formation. Lipid lowering with HMG-CoA reductase inhibitors reduces acute coronary

Articoli

Discover Bioactive Small Molecules for Lipid Signaling Research

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.